Oxford, England – Scripta Therapeutics, a new techbio startup, has emerged from stealth mode and announced a $12 million seed funding round aimed at revolutionizing drug discovery. The company is pioneering a novel approach to developing disease-modifying therapies by targeting transcription factors—proteins that regulate gene expression and play a central role in many diseases. Unlike traditional drug development, which often focuses on enzymes or receptors, Scripta is working to modulate the activity of transcription factors, which are considered "undruggable" by conventional methods. By leveraging advanced computational biology, machine learning, and high-throughput screening, the company aims to identify small molecules and other therapeutics that can precisely control how genes are turned on or off. The seed round, led by prominent life sciences investors, will fuel early-stage research and development, including the expansion of its proprietary platform designed to map and manipulate gene regulatory networks. The company’s long-term goal is to create therapies that go beyond symptom management and instead address the root genetic causes of complex diseases, including rare genetic disorders, cancer, and degenerative conditions. Scripta’s approach represents a significant shift in the drug discovery landscape, where most efforts have historically focused on proteins that are easier to target. By focusing on transcription factors, the company seeks to unlock new treatment avenues for conditions that have seen little progress with current therapies. The team behind Scripta includes experts in genomics, computational biology, and drug development, with deep experience from leading academic institutions and biotech firms. The company is based in Oxford, a global hub for life sciences innovation, and plans to build a robust pipeline of candidates over the next several years. With this initial funding, Scripta aims to validate its platform, generate preclinical data, and position itself for future growth rounds. The company’s mission is to transform how we treat disease by reprogramming the body’s genetic instructions at a fundamental level.